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Red blood cell (RBC) traits are important heritable clinical biomarkers and modifiers of disease severity. To identify coding genetic
variants associated with these traits, we conducted meta-analyses of seven RBC phenotypes in 130,273 multi-ethnic individuals
from studies genotyped on an exome array. After conditional analyses and replication in 27,480 independent individuals, we identified
16 new RBC variants. We found low-frequency missense variants in MAP1A (rs55707100, minor allele frequency [MAF] ¼ 3.3%, p ¼
23 1010 for hemoglobin [HGB]) and HNF4A (rs1800961, MAF ¼ 2.4%, p < 33 108 for hematocrit [HCT] and HGB). In African Amer-
icans, we identified a nonsense variant in CD36 associated with higher RBC distribution width (rs3211938, MAF ¼ 8.7%, p ¼ 73 1011)
and showed that it is associated with lower CD36 expression and strong allelic imbalance in ex vivo differentiated human erythroblasts.
We also identified a rare missense variant in ALAS2 (rs201062903, MAF ¼ 0.2%) associated with lower mean corpuscular volume and
mean corpuscular hemoglobin (p < 8 3 109). Mendelian mutations in ALAS2 are a cause of sideroblastic anemia and erythropoietic
protoporphyria. Gene-based testing highlighted three rare missense variants in PKLR, a gene mutated in Mendelian non-spherocytic
hemolytic anemia, associated with HGB and HCT (SKAT p < 8 3 107). These rare, low-frequency, and common RBC variants showed
pleiotropy, being also associated with platelet, white blood cell, and lipid traits. Our association results and functional annotation sug-
gest the involvement of new genes in human erythropoiesis. We also confirm that rare and low-frequency variants play a role in the
architecture of complex human traits, although their phenotypic effect is generally smaller than originally anticipated.Introduction
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to shear stress and produce the vasodilator nitric oxide to
regulate vascular tonus.1 RBCs participate in antimicrobial
strategies to fight hemolytic pathogens2 and in the inflam-
matory response, acting as a reservoir for multiple chemo-
kines.3 Furthermore, the direct involvement of RBCs in
adhering to the vascular endothelium or supporting
thrombin generation may help to promote blood coagula-
tion or thrombosis.4,5
Given the paramount importance of RBCs in physi-
ology, it is not surprising that monitoring their features
is common practice in medicine to assess the overall
health of patients. An excessive number of circulating
RBCs (erythrocytosis [MIM: 133100]) can suggest a pri-
mary bone marrow disease, a myeloproliferative neoplasm
such as polycythemia vera (MIM: 263300), or chronic
hypoxemia due to congenital heart defects. Low HGB
concentration and hematocrit (HCT) levels (anemia) can
indicate inherited HGB or RBC structural gene mutations,
malnutrition, or kidney diseases. By considering the vol-
ume (mean corpuscular volume [MCV]), hemoglobin con-
tent (mean corpuscular hemoglobin [MCH] and mean
corpuscular hemoglobin concentration [MCHC]) or the
distribution width (RDW) of RBCs, a physician can distin-
guish between the different causes of anemia (e.g., micro-
cytic/hypochromic due to iron deficiency6). In addition,
epidemiological studies have correlated high RDW values
with a worse prognosis in heart failure patients.7 RDW is
also an independent predictor of overall mortality in
healthy individuals, as well as a predictor of mortality in
patients with various conditions such as cardiovascular
diseases, obesity, malignancies, and chronic kidney dis-
ease.8–12
RBC count and indices vary among individuals, and
40%–90% of this phenotypic variation is heritable.13–16
Identifying the genes and biological pathways that
contribute to this inter-individual variation in RBC traits
could highlight modifiers of severity and/or therapeutic
options for several hematological diseases. Already, large-
scale genome-wide association studies (GWASs) have
found dozens of SNPs associated with one or more of
these RBC traits.17,18 However, owing to their design,
GWASs are largely insensitive to rare (minor allele fre-
quency [MAF] < 1%) and low-frequency (1% % MAF <
5%) genetic variants. Using an exome array, we previously
performed an association study for HGB and HCT in
31,340 European-ancestry individuals and identified rare
coding or splice site variants in the erythropoietin and
b-globin genes.19 Within the framework of the Blood-
Cell Consortium (BCX),20,21 we now report a larger geno-
typing-based exome survey of seven RBC traits conducted
in up to 130,273 individuals, including 23,896 partici-
pants of non-European ancestry. With this experiment,
our initial goals were to expand the list of rare and low-
frequency coding or splice site variants associated with
RBC traits and to explore whether the exome array
can complement the GWAS approach to fine map RBC
causal genes.10 The American Journal of Human Genetics 99, 8–21, July 7, 2016Subjects and Methods
Study Participants
The Blood-Cell Consortium (BCX) aims to identify novel common
and rare variants associated with blood-cell traits using an exome
array. BCX is comprised of more than 134,021 participants from
24 discovery cohorts and five ancestries: European, African Amer-
ican, Hispanic, East Asian, and South Asian. Detailed description
of the participating cohorts is provided in Table S1. BCX is inter-
ested in the genetics of all main hematological measures and is
divided into three main working groups: RBC, white blood cell
(WBC),21 and platelet (PLT).20 For the RBC working group, we
analyzed seven traits available in up to 130,273 individuals: RBC
count (31012/L), HGB (g/dL), HCT (%), MCV (fL), MCH (pg),
MCHC (g/dL), and RDW (%) (Table S2). The BCX procedures
were in accordance with the institutional and national ethical
standards of the responsible committees and proper informed
consent was obtained.Genotyping and Quality-Control Steps
Participants from the different studies were genotyped on one of
the following exome chip genotyping arrays: Illumina Exome-
Chip v.1.0, Illumina ExomeChip v.1.1_A, Illumina ExomeChip-
12 v.1.1, Affymetrix Axiom Biobank Plus GSKBB1, or Illumina
HumanOmniExpressExome Chip. Genotypes were then called
either (1) with the Illumina GenomeStudio GENCALL and subse-
quently recalled using zCALL or (2) by the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) Consortium
Exome Chip effort22 (Table S3). The same quality-control steps
were followed by each participating study. We excluded variants
with low genotyping success rate (<95%, except for WHI that
used a cutoff <90%) (Table S3). Samples with call rate < 95%
(except for SOLID-TIMI 52 and STABILITY that used 94.5% and
93.5% cutoffs, respectively) after joint or zCALL calling and with
outlying heterozygosity rate were also excluded. Other exclusions
were deviation from Hardy-Weinberg equilibrium (p < 1 3 106)
and gender mismatch. We performed principal-component anal-
ysis (PCA) or multidimensional scaling (MDS) and excluded sam-
ple outliers from the resulting plots through visual inspection,
using populations from the 1000 Genomes Project to anchor these
analyses. Keeping only autosomal and X chromosome variants for
the analysis, we aligned all variants on the forward strand and
created a uniform list of reference alleles using the --force alleles
command in PLINK.23 Finally, an indexed variant call format file
(VCF) was created by each study and checked for allele alignment
and any allele or strand flips using the checkVCF package.24 Prior
to performing meta-analyses of the association results provided by
each participating study, we ran the EasyQC protocol25 to check
for population allele frequency deviations and proper trait trans-
formation in each cohort.Phenotype Modeling and Association Analyses
When possible, we excluded individuals with blood cancer, leuke-
mia, lymphoma, bone marrow transplant, congenital or heredi-
tary anemia, HIV, end-stage kidney disease, dialysis, splenectomy,
or cirrhosis and those with extreme measurements of RBC traits
(Table S1). We also excluded individuals on erythropoietin treat-
ment or chemotherapy. Additionally, we excluded pregnant
women and individuals with acute medical illness at the time
the complete blood count (CBC) was done. For the seven RBC
traits, within each study, we adjusted for age, age-squared, gender,
the first ten principal components, and, where applicable, other
study-specific covariates such as study center via a linear regres-
sion model. Within each study, we then applied inverse normal
transformation on the residuals and tested the phenotypes for as-
sociation with the ExomeChip variants using either RVtests
(v.20140416)26 or RAREMETALWORKER.0.4.9.27Discovery Meta-analyses
Score files generated by RVtests or RAREMETALWORKER from
each participating study were used to carry out meta-analyses of
the single variant association results using RareMETALS v.5.9.28
All analyses were performed separately in each of European
American (EA) and African American (AA) ancestries. In the
multi-ancestry meta-analyses, we combined individuals of Euro-
pean, African American, Hispanic, East-Asian, and South-Asian an-
cestries (All). We included variants with allele frequency difference
between the highest and lowest MAF < 0.3 for EA and AA ances-
tries and < 0.6 for the combined ancestry meta-analyses. For the
gene-based analyses, we used score files and variance-covariance
matrices from the study-specific association results and applied
the sequence kernel association test (SKAT)29 and variable
threshold (VT) algorithms30 in RareMETALS considering only
missense, nonsense, and splice site variants with a MAF < 1%.
Gene-based analyses were also stratified by ancestry. Significance
thresholds were determined using Bonferroni correction assuming
~250,000 independent variants (p < 2 3 107 for the single-
variant analyses) and ~17,000 genes tested on the ExomeChip
(p < 3 3 106 for the gene-based tests).Conditional Analysis and Replication
In order to identify independent signals, we performed condi-
tional analyses. In each round of conditional analysis, we condi-
tioned on the most significant single variant in a 1 Mb window.
These conditional analyses were performed at the meta-analysis
level using RareMETALS. We repeated this step until there
were no new signals identified in each region, defined as p <
23 107. We then checked for linkage disequilibrium (LD) within
the list of variants that was retained from the conditional analyses.
For variants that were inmoderate-to-strong LD (r2R 0.3), we kept
the most significant. We attempted replication of the final list of
independent variants in eight additional studies that contributed
a total of 27,480 individuals (n ¼ 21,473 for EA and n ¼ 6,007
for AA) (Table S4). The division of discovery and replication sam-
ples was dictated by timing because we collected all groups we
were aware of for initial discovery and then found others who
could participate only much later and hence were used for replica-
tion. These studies followed similar analytical procedures and
steps as those followed by the discovery analysis (see above).
A joint meta-analysis of the discovery and the replication results
was carried out using a fixed-effects model and inverse-variance
weighting as implemented in METAL.31 We considered as repli-
cated markers those with a nominal preplication< 0.05 and an effect
on phenotype in the same direction as in the discovery results.Allelic Imbalance and Expression of CD36
We checked for allelic imbalance (AI) of the rs3211938 variant in
CD36 (MIM: 173510) as well as the expression of the gene in 12
samples of fetal liver erythroblasts obtained from anonymous do-
nors. Details on the protocol including RNA extraction
and sequencing can be found elsewhere.32 We calculated the
difference in the ratio of reads of the reference allele (T) and theTalternate allele (G) of rs3211938. In brief, reads overlapping
rs3211938 were counted with samtools (v.1.1) mpileup software
using genome build hg19. We kept uniquely mapping reads using
-q 50 argument (mapping quality > 50) and sites with base
quality > 10. Statistical significance of the difference in the ratio
of reads between the reference allele and the alternate allele was
assessed with a binomial test. For each sample, we summed all
reads overlapping all heterozygous SNPs and calculated the ex-
pected ratio within each SNP allele combination. Reads that fall
in the top 25th coverage percentile were down-sampled so that
the highest covered sites do not bias the expected ratio.33 For
rs3211938, the expected T:G ratio was 0.507.Expression Quantitative Trait Loci Analysis
We cross-referenced our list of RBC novel variants with more than
100 separate expression quantitative trait loci (eQTL) published
datasets. Datasets were collected through publications, publically
available sources, and private collaborations. A general overview
of a subset of>50 eQTL studies has been published,34 with specific
citations for >100 datasets included in the current query followed
here. A complete list of tissues and studies used can be found in the
Supplemental Data. We considered SNPs that are themselves
expression SNPs (eSNP) when they meet a p < 0.0001 threshold
or when they are in LD (r2 > 0.3) with the best eSNP (p < 0.0001).Results
Single-Variant Meta-analyses
We meta-analyzed ExomeChip results for seven RBC-
related phenotypes (RBC count, HCT, HGB, MCH,
MCHC, MCV, and RDW) available in up to 130,273 indi-
viduals from 24 studies and 5 ancestries (Tables S1–S3
and Figure S1). Across these different phenotypes, a total
of 226 variants reached exome-wide significance (p <
2 3 107) in the combined ancestry analyses (Figures 1
and S2). Given that some of these RBC traits are correlated
(Figure S3), these associated variants highlight 71 different
loci (defined using a 1 Mb interval). Overall, we observed
only modest inflation of the test statistics (lGC ¼ 1.03–
1.05), consistent with little confounding due to technical
artifacts, population stratification, or cryptic relatedness.
In order to identify independent variants, we performed
conditional analyses at the meta-analysis level adjusting
for the effect of the most significant variant in a 1 Mb
region in a stepwise manner (Subjects and Methods).
After this analysis, we obtained a list of 126 indepen-
dent variants associated with at least one RBC trait at p <
2 3 107 (Table S5). Selecting only variants that lie more
than 1 Mb away from a known GWAS locus resulted in
23 independent variants located within 20 novel RBC
loci, where novel is used to define loci not found in the ex-
isting literature (Table 1). We attempted to replicate these
126 variants in 8 independent cohorts totaling 27,480
participants (Table S5). Overall, we observed a strong repli-
cation, with 94 of the 126 variants showing consistent
direction of effect between the discovery and replication
analyses (binomial p¼ 33 108; Table S5). Of the 23 novel
RBC variants, we replicated 16 at nominal p < 0.05 for athe American Journal of Human Genetics 99, 8–21, July 7, 2016 11
Figure 1. Quantile-Quantile Plots of Single-Variant Association Results in the All AncestryMeta-analyses for the Seven Red Blood Cell
Traits Analyzed
(A) Distribution of the single variant results for all variants tested on the exome array.
(B) Only markers with a minor allele frequency < 5% are shown here.
(C) Variants outside of known RBC GWAS regions. Variants that are within 1 Mb from a previously published RBC GWAS locus were
excluded for this QQ plot.
Abbreviations are as follows: HCT, hematocrit; HGB, hemoglobin; RBC, red blood cell count; MCV, mean corpuscular volume; MCHC,
mean corpuscular hemoglobin concentration; MCH, mean corpuscular hemoglobin; RDW, red blood cell distribution width.least one RBC trait (binomial p ¼ 3 3 1016; Table 1). Out
of these 16 novel and replicated RBC variants, there are five
missense variants, including two variants with MAF < 5%
in MAP1A (MIM: 600178) and HNF4A (MIM: 600281) and
one nonsense variant in CD36 (Table 1). Among the re-
maining nine novel and replicated RBC variants, there
are five intronic, one synonymous, one 50 UTR, and one in-
tergenic marker (Table 1).
Prioritization of Candidate Genes and Genetic
Variants
Our single-variant analyses in EA samples identified one
rare missense variant in ALAS2 (MIM: 301300) associated
with MCV and MCH (rs201062903, p.Pro507Leu
[c.1559C>T], MAF ¼ 0.2%) (Table 1). The association
with this variant did not replicate, potentially because of
limited statistical power (the replication sample size for
this rare marker was 5,044; see also Discussion). ALAS2 en-
codes 5-aminolevulinate synthase 2, the rate-controlling
enzyme of erythroid heme synthesis. Additionally, rare
mutations in ALAS2 cause X-linked sideroblastic anemia
(MIM: 300751) and erythropoietic protoporphyria (MIM:
300752). Thus, despite the lack of replication, ALAS2
remains an excellent candidate gene to modulate RBC
traits. The ALAS2 p.Pro507Leu variant, which is not re-
ported in the ClinVar database, maps between two amino
acids (Tyr506 and Thr508) that are important for catalytic
activity and known to be mutated in cases of sideroblastic
anemia.35
Two low-frequency missense variants identified in our
analyses implicate MAP1A and HNF4A in RBC biology
(Table 1). MAP1A encodes microtubule-associated protein
1A, a gene highly expressed in the nervous system and
mostly studied in the context of neuronal diseases,
although it is expressed in many additional tissues,12 The American Journal of Human Genetics 99, 8–21, July 7, 2016including hematopoietic cells.36 Deletion of MAP1A in
the mouse causes defects in synaptic plasticity.37 This
observation is interesting given that inactivation of
ANK1 (MIM: 612641), another gene that encodes a cyto-
skeleton protein and is expressed in neurons and RBCs, is
associated with neurological dysfunction in the mouse
and spherocytosis and hemolytic anemia in humans
(MIM: 182900). Our meta-analyses confirmed two known
independent ANK1 variants associated with MCHC: an in-
tronic SNP (rs4737009, MAF ¼ 19.8%, p ¼ 1.3 3 108)
and a low-frequency missense variant (rs34664882,
p.Ala1462Val, MAF ¼ 2.9%, p ¼ 1.7 3 1016) (Table S5;
N.P., U.M.S., J.B.-J., and M.-H.C., unpublished data).17
In the accompanying BCX PLT article,20 we report that
the same MAP1A rs55707100 allele (p.Pro2349Leu
[c.7046C>T]) associated here with decreased HGB concen-
tration is also associated with increased PLTcount. Further-
more, recent studies have identified associations between
rs55707100 and HDL-cholesterol and triglyceride levels
(S. Mukherjee, 2015, ASHG, conference). Adding to the
complexity, the GTEx dataset indicates that rs55707100
is an expression quantitative trait locus (eQTL) for ADAL
(peQTL ¼ 93 1011) but not forMAP1A.38 ADAL is a poorly
characterized adenosine deaminase-like protein that is
highly expressed in human erythroblasts. However, the
eQTL association between rs55707100 and ADAL could
simply reflect ‘‘LD shadowing’’ from nearby markers that
are much stronger eQTL variants for ADAL. Indeed,
rs3742971 (a common variant located in ADAL’s 50 UTR)
is in partial LD with rs55707100 (r2 ¼ 0.18 in Eu-
ropean populations from the 1000 Genomes Pro-
ject) and strongly associated with ADAL expression levels
(peQTL ¼ 6 3 1049).
The second low-frequency missense variant associated
with HGB and HCT maps within the coding sequence of
Table 1. Association Results of Variants in Novel Loci Associated with Red Blood Cell Traits
Marker Info Discovery Replication Combined
Trait Position A1/A2 SNP Annotation Gene n AF (A2) Beta (SE) p Value n AF (A2) Beta (SE) p Value Beta (SE) p Value
RDW-EA 1: 25,768,937 A/G rs10903129* intron TMEM57-RHD 45,573 0.544 0.037 (0.007) 1.19 3 107 18,475 0.560 0.023 (0.011) 0.0373 0.033 (0.006) 2.41 3 108
RDW-All 1: 25,768,937 A/G rs10903129* intron TMEM57-RHD 56,194 0.568 0.034 (0.006) 9.58 3 108 24,474 0.600 0.021 (0.01) 0.0252 0.03 (0.005) 1.32 3 108
HCT-All 1: 155,162,067 C/T rs4072037* synonymous MUC1 109,875 0.554 0.025 (0.005) 5.82 3 108 25,006 0.563 0.038 (0.009) 5.96 3 105 0.027 (0.004) 3.47 3 1011
HGB-All 2: 27,741,237 T/C rs780094 intron GCKR 130,273 0.626 0.024 (0.004) 7.14 3 108 3,162 0.626 0.012 (0.026) 0.6410 0.023 (0.044) 1.68 3 107
RBC-All 2: 219,509,618 C/A rs2230115* missense ZNF142 74,488 0.509 0.033 (0.006) 9.74 3 109 27,442 0.477 0.024 (0.01) 0.0167 0.031 (0.005) 7.11 3 1010
HCT-All 3: 56,771,251 A/C rs3772219* missense ARHGEF3 109,875 0.338 0.028 (0.005) 2.38 3 109 25,006 0.366 0.021 (0.01) 0.0292 0.027 (0.004) 2.56 3 1010
HGB-All 3: 56,771,251 A/C rs3772219* missense ARHGEF3 130,273 0.336 0.026 (0.004) 3.76 3 109 27,749 0.367 0.02 (0.009) 0.0331 0.025 (0.004) 4.33 3 1010
HCT-EA 4: 88,008,782 G/A rs236985 intron AFF1 87,444 0.394 0.032 (0.005) 3.89 3 1010 19,968 0.405 0.02 (0.011) 0.0626 0.03 (0.005) 1.14 3 1010
RBC-EA 4: 88,008,782 G/A rs236985* intron AFF1 60,231 0.393 0.034 (0.006) 3.50 3 108 21,435 0.405 0.023 (0.011) 0.0273 0.031 (0.005) 4.22 3 109
HGB-EA 4: 88,030,261 G/T rs442177* intron AFF1 106,377 0.595 0.034 (0.005) 3.97 3 1013 21,743 0.586 0.029 (0.01) 0.0052 0.033 (0.004) 8.23 3 1015
RDW-EA 5: 127,371,588 A/G rs10063647* intron LINC01184-
SLC12A2
45,573 0.463 0.05 (0.007) 1.72 3 1013 18,475 0.480 0.033 (0.011) 0.0018 0.045 (0.006) 2.88 3 1015
RDW-All 5: 127,371,588 A/G rs10063647* intron LINC01184-
SLC12A2
56,194 0.506 0.044 (0.006) 2.11 3 1012 24,474 0.545 0.03 (0.01) 0.0014 0.04 (0.005) 2.37 3 1014
RDW-EA 5: 127,522,543 C/T rs10089* utr_5p LINC01184-
SLC12A2
45,573 0.21 0.051 (0.008) 8.45 3 1010 16,692 0.215 0.058 (0.014) 2.71 3 105 0.053 (0.007) 1.15 3 1013
RDW-All 5: 127,522,543 C/T rs10089* utr_5p LINC01184-
SLC12A2
56,194 0.207 0.044 (0.008) 4.08 3 109 22,691 0.208 0.045 (0.012) 0.0001 0.044 (0.006) 2.73 3 1012
HGB-All 6: 7,247,344 C/A rs35742417* missense RREB1 130,273 0.174 0.030 (0.005) 1.17 3 108 4,074 0.207 0.065 (0.028) 0.0190 0.032 (0.005) 1.50 3 109
RDW-AA 7: 80,300,449 T/G rs3211938* nonsense CD36 6,666 0.087 0.174 (0.031) 2.36 3 108 5,999 0.086 0.139 (0.032) 1.83 3 105 0.161 (0.025) 7.09 3 1011
RDW-All 7: 80,300,449 T/G rs3211938* nonsense CD36 55,510 0.012 0.171 (0.029) 5.29 3 109 22,691 0.023 0.139 (0.032) 1.61 3 105 0.157 (0.022) 5.12 3 1013
RDW-EA 8: 126,490,972 A/T rs2954029* intergenic TRIB1 45,573 0.46 0.036 (0.007) 1.53 3 107 16,692 0.466 0.026 (0.011) 0.0210 0.034 (0.006) 1.29 3 108
RDW-All 8: 126,490,972 A/T rs2954029* intergenic TRIB1 56,194 0.439 0.032 (0.006) 1.83 3 107 22,691 0.432 0.021 (0.01) 0.0298 0.029 (0.005) 2.54 3 108
MCH-All 10: 105,659,826 T/C rs2487999 missense OBFC1 66,318 0.869 0.047 (0.009) 4.12 3 108 26,749 0.861 0.025 (0.013) 0.0601 0.041 (0.007) 1.75 3 108
MCH-AA 11: 92,722,761 G/A rs1447352 intergenic MTNR1B 8,273 0.557 0.089 (0.016) 1.85 3 108 5,038 0.562 0.022 (0.02) 0.2713 0.07 (0.014) 1.08 3 106
HGB-EA 15: 43,820,717 C/T rs55707100* missense MAP1A 106,377 0.033 0.071 (0.013) 1.65 3 108 21,743 0.0223 0.099 (0.033) 0.0028 0.075 (0.012) 2.31 3 1010
MCV-AA 16: 1,551,082 A/G rs2667662* intron TELO2 10,849 0.725 0.099 (0.015) 1.79 3 1010 5,034 0.724 0.093 (0.022) 3.02 3 105 0.098 (0.014) 7.32 3 1012
MCV-AA 16: 2,812,939 C/A rs2240140* missense SRRM2 8,525 0.118 0.134 (0.025) 7.08 3 108 6,002 0.124 0.106 (0.027) 0.0001 0.128 (0.022) 5.24 3 109
(Continued on next page)
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Table 1. Continued
Marker Info Discovery Replication Combined
Trait Position A1/A2 SNP Annotation Gene n AF (A2) Beta (SE) p Value n AF (A2) Beta (SE) p Value Beta (SE) p Value
HCT-EA 17: 59,017,025 T/C rs8080784 intron BCAS3-TBX2 79,344 0.158 0.039 (0.007) 2.62 3 108 19,968 0.148 0.011 (0.014) 0.4349 0.029 (0.006) 3.39 3 106
HGB-EA 17: 59,483,766 C/T rs8068318 intron BCAS3-TBX2 106,377 0.722 0.026 (0.005) 1.53 3 107 21,743 0.730 0.021 (0.011) 0.0565 0.025 (0.005) 2.55 3 108
MCV-EA 20: 31,140,165 C/T rs4911241* intron NOL4L 61,462 0.241 0.04 (0.007) 1.25 3 108 21,714 0.252 0.025 (0.012) 0.0302 0.036 (0.006) 2.01 3 109
RDW-EA 20: 31,140,165 C/T rs4911241* intron NOL4L 45,573 0.242 0.043 (0.008) 5.79 3 108 18,475 0.240 0.049 (0.012) 7.44 3 105 0.045 (0.007) 2.01 3 1011
RDW-All 20: 31,140,165 C/T rs4911241* intron NOL4L 56,194 0.235 0.038 (0.007) 1.56 3 107 24,474 0.222 0.044 (0.011) 6.10 3 105 0.04 (0.006) 4.60 3 1011
HCT-EA 20: 43,042,364 C/T rs1800961* missense HNF4A 79,344 0.024 0.083 (0.015) 1.44 3 108 19,968 0.033 0.082 (0.028) 0.0037 0.083 (0.013) 1.91 3 1010
HGB-EA 20: 43,042,364 C/T rs1800961* missense HNF4A 98,277 0.032 0.073 (0.013) 2.53 3 108 21,743 0.032 0.062 (0.027) 0.0232 0.071 (0.012) 1.93 3 109
HCT-All 20: 43,042,364 C/T rs1800961* missense HNF4A 100,313 0.022 0.077 (0.014) 2.31 3 108 25,006 0.027 0.091 (0.028) 0.0010 0.08 (0.012) 9.88 3 1011
HGB-All 22: 44,324,727 C/G rs738409 missense PNPLA3 130,273 0.223 0.028 (0.005) 2.24 3 108 4,074 0.218 0.053 (0.027) 0.0504 0.029 (0.005) 4.81 3 109
MCH-EA X: 55,039,960 G/A rs201062903 missense ALAS2 52,758 0.002 0.324 (0.053) 7.32 3 1010 5,855 0.001 0.291 (0.235) 0.215 0.323 (0.052) 5.81 3 1010
MCH-All X: 55,039,960 G/A rs201062903 missense ALAS2 65,067 0.002 0.322 (0.051) 3.36 3 1010 10,893 0.001 0.276 (0.224) 0.218 0.321 (0.051) 2.68 3 1010
MCV-EA X: 55,039,960 G/A rs201062903 missense ALAS2 60,211 0.002 0.285 (0.049) 7.11 3 109 5,044 0.001 0.178 (0.248) 0.472 0.282 (0.049) 6.11 3 109
Variants in novel loci with p< 23 107 and that were retained after conditional analyses are presented here. All variants are>1Mb apart from a known GWAS signal for RBC traits. Chromosome positions are given on human
genome build hg19. Allele frequency and effect size are given for the alternate (A2) allele. Replication was carried out in six cohorts for EA and two cohorts for AA and was performed in RareMetals; meta-analyses of the
discovery and replication cohorts are presented under ‘‘Combined’’ and were carried out in METAL. Asterisks (*) indicate variants that replicated with a nominal p< 0.05. Abbreviations are as follows: EA, European American;
AA, African American; All, combined ancestry (EA þ AA þ Asians þ Hispanics); A1, reference allele; A2, alternate allele; N, sample size; AF, allele frequency; SE, standard error; HCT, hematocrit; HGB, hemoglobin; RBC, red
blood cell count; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; MCH, mean corpuscular hemoglobin; RDW, red blood cell distribution width.
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Figure 2. CD36 Expression in Human
Erythroblasts
(A) In a dataset of 12 human fetal liver
erythroblasts, all samples were homozy-
gous at rs3211938 for the reference T-allele
with the exception of one heterozygous
sample (FL11). FL11 demonstrated strong
allelic imbalance: we observed 705 reads
for the reference allele (T) and 126
reads for the alternate allele (G) (binomial
p ¼ 4.9 3 1095).
(B) FL11 (in green) shows the lowest
CD36 expression level when compared to
the other 11 samples. Abbreviation is as
follows: FPKM, fragments per kilobase of
transcript per million mapped reads.the transcription factor HNF4A (Table 1). This marker,
rs1800961 (p.Thr117Ile [c.350C>T]), has previously been
associated with HDL and total cholesterol, C-reactive pro-
tein, fibrinogen, and coagulation factor VII levels.39–42 Mu-
tations in HNF4A cause maturity-onset diabetes of the
young (MODY [MIM: 125851]) and a common intronic
SNP in HNF4A (rs4812829) has been associated with
type 2 diabetes (MIM: 125853) risk.43 The missense
rs1800961 associated with HGB and HCT is only in weak
LD with rs4812829 (r2 ¼ 0.021 in EA populations from
the 1000 Genomes Project). Querying recently released
ExomeChip data from Type 2 Diabetes Genetics (Web Re-
sources), we found that rs1800961 is also associated with
T2D risk in ~82,000 participants (p ¼ 9.5 3 107, odds
ratio ¼ 1.16). HNF4A is expressed in the kidney and could
influence HGB andHCT through the regulation of erythro-
poietin production.44 It is also abundantly expressed in the
liver, where it could indirectly affect HGB and HCT levels
through an effect on blood lipid levels (see Discussion).
HNF4A is detectable at low levels in erythroblasts, and
the BLUEPRINT Project has found that some HNF4A iso-
forms may be more highly expressed in this cell type
(Figure S4).45
In AA, we identified a nonsense variant (rs3211938,
p.Tyr325Ter [c.975T>G], MAF ¼ 8.7%, p ¼ 7.1 3 1011)
in CD36 associated with RDW. This variant displays a
wide variation in allele frequency between AA and EA
(MAFEA ¼ 0.01%). The association is slightly improved in
the ancestry-combined meta-analysis (p ¼ 5.1 3 1013)
because there is also evidence of association in Hispanics
(MAF ¼ 1.9%, p ¼ 0.022) (Table 1). We examined a dataset
of ex vivo differentiated human erythroblasts to determine
whether this CD36 nonsense variant shows allelic imbal-
ance (AI).32 All samples were homozygous at rs3211938
for the reference allele with the exception of one heterozy-
gous sample (FL11). FL11 had the lowest level of CD36
expression among the 12 samples tested and demonstrated
strong AI where we observe 705 sequence reads for the
reference allele (T) versus 126 for the alternate allele (G)
(p¼ 4.93 1095; Figure 2). To confirm this finding in inde-
pendent samples, we queried the GTEx dataset, which hasTcompiled RNA-sequencing and genotype information
from multiple human tissues.38 GTEx does not include
data for human erythroblasts. However, it detected a
strong eQTL effect of rs3211938 on CD36 expression in
whole blood (peQTL ¼ 1.1 3 1015), with carriers of the
G-allele expressing less CD36 (Figure S5). Furthermore,
GTEx reported evidence for moderate AI inmultiple tissues
for CD36-rs3211938, with the G-allele being under-repre-
sented among sequence reads (Figure S5). These results
strongly support our observations in human erythroblasts.
eQTL Analysis
To prioritize additional causal genes at RBC loci that
contain non-coding variants, we cross-referenced our list
of novel variants withmore than 100 published eQTL data-
sets (Subjects and Methods). Overall, 12 variants were sig-
nificant eQTLs in a wide variety of tissues (Table S6). The
most interesting eQTL finding is the association between
rs10903129, a common marker associated with RDW in
our analyses and located within an intron of TMEM57
(MIM: 610301), and the expression of RHD (MIM:
111680) in whole blood. RHD is located 112 kb down-
stream of TMEM57 and encodes the D antigen of the clin-
ically significant Rhesus (Rh) blood group. rs10903129 has
also been associated with total cholesterol levels and eryth-
rocyte sedimentation rate (ESR).46,47 The association with
ESR is particularly intriguing given that it is considered a
non-specific indicator of inflammation. As described
above, RDW is also abnormal in chronic diseases, such as
atherosclerosis and diabetes, which have an important
inflammation component.
Gene-Based Association Testing
Despite our large sample size, statistical power remains
limited for rare variants ofweak-to-moderate phenotypic ef-
fect. To try to capture these genetic factors, we performed
gene-based testing by aggregating coding and splice site var-
iants with MAF < 1% within each gene (Subjects and
Methods). The SKAT analyses identified two genes: ALAS2
associated with MCH and PKLR (MIM: 609712) associated
with HGB and HCT (Table 2). The ALAS2 signal was drivenhe American Journal of Human Genetics 99, 8–21, July 7, 2016 15
Table 2. Gene-Based Association Results
Trait Gene n
Number of
Variants Analyzed
VT SKAT
Top Variant Top-Variant MAF Top-Variant p Valuep Value p Value
HGB-EA PKLR 106,377 15 1.92 3 105 7.02 3 107 rs116100695 0.003 1.17 3 105
HGB-All PKLR 130,273 15 0.00016 6.57 3 107 rs116100695 0.003 1.94 3 105
HCT-All PKLR 109,875 15 3.96 3 105 7.95 3 107 rs116100695 0.003 2.49 3 105
MCH-EA ALAS2 54,009 11 4.78 3 106 5.79 3 107 rs201062903 0.002 7.32 3 1010
MCHC-All ALPK3 84,841 28 1.95 3 106 0.793 rs202037221 3.0 3 105 0.0005
Gene-based results of the VT and SKAT algorithms for genes associated with RBC traits at p < 3 3 106. We analyzed non-synonymous coding (nonsense,
missense) and splice site variants with a minor allele frequency (MAF) < 1%. Abbreviations are as follows: EA, European American; All, combined ancestry
(EA þ AA þ Asians þ Hispanics); n, sample size; HCT, hematocrit; HGB, hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCH, mean corpus-
cular hemoglobin.by a single rare missense variant (rs201062903) and was
described above. PKLR encodes the erythrocyte pyruvate ki-
nase (PK) that catalyzes the last step of glycolysis. PK defi-
ciency, usually caused by recessive mutations, is one of the
main causes of non-spherocytic hemolytic anemia (MIM:
266200). In fact, one of the variants identified in our meta-
analysis (rs116100695, p.Arg486Trp [c.1456T>G], MAF ¼
0.3%, betaHGB ¼ 0.242 g/dl, pHGB ¼ 1.2 3 105) is a
frequent cause of PK deficiency in Italian and Spanish sub-
jects.48,49 This variant was confirmed in the replication co-
horts (preplication ¼ 0.039; Table S7). Two additional PKLR
rare missense variants contribute to the gene-based associa-
tion statistic with HGB andHCT: rs61755431 (p.Arg569Gln
[c.1706G>A], MAF ¼ 0.2%, betaHGB ¼ 0.179 g/dl, pHGB ¼
0.006) and rs8177988 (p.Val506Ile [c.1516G>A], MAF ¼
0.6%, betaHGB ¼ þ0.116 g/dl, pHGB ¼ 0.003). It is note-
worthy that the p.Val506Ile substitution is associated with
increased HGB concentration given that this amino acid
maps to a PKLR structural domain necessary for protein
interaction.50 This heterogeneity of effect among the PKLR
missense variants might explain why SKAT’s result is
more significant than VT’s for this gene (Table 2). A third
gene, ALPK3, was identified only in the VT analysis for
association with MCHC (Table 2). ALPK3 encodes a kinase
previously implicated in cardiomyocyte differentiation.51
We could not test for replication because of the rarity of
ALPK3’s coding alleles (Table S7).
RBC Variants and Pleiotropic Effects
Besides the overlap within the RBC traits themselves, we
identified seven novel RBC variants associated with other
blood-cell type traits or with lipid levels (Figure 3 and Ta-
ble 3). To assess whether the genetic associations with
RBC traits are independent of lipid levels, we performed
additional analyses in a subset of BCX participants from
three of our studies (FHS, MHIBB, and WHI) ranging
from ~10,000 to 23,000 individuals. We repeated the
association analyses for five RBC loci (TMEM57-RHD
rs10903129, AFF1 rs442177, TRIB1 rs2954029, MAP1A
rs55707100, andHNF4A rs1800961) additionally adjusting
for the respective lipid trait and combined the results
across the three studies using fixed-effect meta-analysis16 The American Journal of Human Genetics 99, 8–21, July 7, 2016(Table S8). There was little or no change in the effect size
or p values associated with the five RBC trait loci upon
adjustment for the corresponding lipid trait, suggesting
that the RBC and lipid associations are independent of
one another and thus represent true ‘‘pleiotropic’’ genetic
effects.
A correlated response to or role in inflammation might
explain why some of the RBC variants are also associated
with WBC, PLT, or lipid traits. Another plausible explana-
tion for the concomitant association of several markers
with RBC,WBC, and PLT phenotypes could be a more gen-
eral effect of these genes on the proliferation or differentia-
tion of hematopoietic progenitor cells. This is most
likely the case for JAK2 (MIM: 147796) and SH2B3
(MIM: 605093), two key regulators of hematopoietic cells
(Figure 3). In this category, we also observed twonovel find-
ings,AFF1 (MIM: 159557) andNOL4L, which are associated
with RBC and WBC phenotypes and have been previously
implicated in leukemia.53,54 Finally, we identified a novel
missense variant in ARHGEF3 (MIM: 612115) associated
with HGB and HCT. In addition to its association with
PLT traits, ARHGEF3 plays a role in the regulation of iron
uptake and erythroid cell maturation.55Discussion
We present multi-ethnic meta-analyses of seven RBC traits
using ExomeChip results of 130,273 individuals. Our sta-
tistical thresholds to declare significance at the discovery
stage (p < 2 3 107 in the single-variant analyses) was
adjusted for the approximate number of variants geno-
typed on the ExomeChip (Bonferroni correction for
250,000 variants), but we decided not to adjust it for the
seven RBC phenotypes tested because of the high correla-
tion between some of these traits (Figure S3). Instead, we
relied on independent replication to distinguish true
from probably false positive associations. Despite the
limited size of our replication set (27,480 individuals), it
was encouraging to detect a strong replication of direction
of effect for known and novel RBC variants, suggesting a
low false discovery rate. In total, we identified 23 novel
Figure 3. Venn Diagram Summarizing Pleiotropic Effects for
Genetic Variants Associated with Red Blood Cell Traits
We considered variants only if their association p values with
white blood cell (WBC) traits, platelet (PLT) traits, or with lipid
levels was p < 1 3 104. Results for WBC and PLT are from the
accompanying Blood-Cell Consortium articles.20,21 Results for
lipids have previously been published (Table 3). Genes highlighted
in red are novel RBC trait findings.variants associated with RBC traits in the single-variant an-
alyses and a collection of three rare missense variants in
PKLR associated with HGB and HCT in the gene-based an-
alyses. Out of the 23 novel RBC variants, 16 were replicated
at p < 0.05 in the independent samples (Table 1). To
inform our replication criteria, we conducted a power anal-
ysis using a sample size of 20,000 and considering multiple
combinations of allele frequencies and effect sizes. Based
on allele frequency and effect size, one of our most difficult
to replicate variants was rs1800961 (MAF ¼ 0.022, Beta ¼
0.028). However, we still had approximately 56% power
to detect this association in the replication stage.
We identified a nonsense variant in CD36 associated
with RDW in African Americans. CD36 is a type B scav-
enger receptor located on the surface of many cell types,
including endothelial cells, platelets, monocytes, and
erythrocytes. CD36 is a marker of erythroid progenitor dif-
ferentiation56 and might also be involved in macrophage-
mediated clearance of red blood cells.57 Furthermore,
CD36 plays a role in many biological pathways such as
lipid metabolism/transport and atherosclerosis, hemosta-
sis, and inflammation.58 The nonsense CD36 variant iden-
tified in our RDW meta-analysis (rs3211938, Table 1) has
previously been associated with platelet count, HDL
cholesterol, and C-reactive protein levels in African Amer-
icans59,60 andmalaria resistance in Africans.61,62 The CD36
locus shows a signature of natural selection in AA popula-
tions63 and the MAF of rs3211938 varies widely betweenTcontinents: in the 1000 Genomes Project, the minor allele
is absent from European populations but reaches fre-
quency of 24%–29% in some African populations.64 To
characterize the molecular mechanism by which
rs3211938 can impact RDW, we identified one heterozy-
gous sample among a collection of ex vivo differentiated
human erythroblasts.32 In erythroblasts from this donor,
we noted a strong allelic imbalance (Figure 2). Importantly,
this result was confirmed in independent samples from the
GTex dataset (Figure S5). At the molecular level, this CD36
expression phenotype could be explained by nonsense-
mediated mRNA decay or the regulatory effect of non-cod-
ing genetic variants in LD with rs3211938.
We observed that many new RBC variants are pleio-
tropic, being often associated with more than one RBC in-
dex as well as with WBC, PLT, and lipid traits (Figure 3).
These shared effects could imply that the underlying
causal genes at these RBC loci generally controlled blood
cell proliferation or modulate inflammatory responses.
An additional explanation for the link between RBC traits
and lipid variants might be the cholesterol content of RBC
membranes. As mentioned earlier, RBC corresponds to a
large fraction (~25%) of the cells found in the human
body. Genetic variation that modulates RBC count or vol-
ume could impact circulating lipid levels. In support of this
hypothesis, it has been observed that a thalassemia allele is
strongly associated with cholesterol levels in the Sardinian
population.65 In total, we found ten loci associated with
lipid levels and RBC indices, including four novel RBC var-
iants (AFF1, TMEM57-RHD, TRIB1, HNF4A) (Figure 3).
In summary, our multi-ethnic meta-analyses have
expanded the genetic knowledge of erythrocyte biology
and identified new common, low-frequency, and rare RBC
variants. Many of the new RBC variants are pleiotropic,
affecting other complex traits such asWBC, PLT, and blood
lipid levels. Although our report demonstrates the utility of
the ExomeChip for genetic discovery, it also highlights the
challenge to attribute gene causality based only on associa-
tion results. This is particularly evident for loci with com-
mon variants, for which coding and non-coding markers
are often statistically equivalent. For instance, we found
no examples of RBC coding variants that entirely explain
RBC GWAS signals among the seven loci that had both a
sentinel GWAS variant and ExomeChip coding markers.
Although increasing sample sizes will continue to yield
additional RBC loci, it has become incredibly clear that
only a combination of well-powered genetic studies, tran-
scriptomic and epigenomic surveys, and functional experi-
ments (e.g., using genome editing) will ultimately pinpoint
causal variants and genes that control RBC phenotypes.Supplemental Data
Supplemental Data include a note on the eQTL analyses, informa-
tion on supplementary funding, five figures, and eight tables and
can be found with this article online at http://dx.doi.org/10.1016/
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Table 3. Overlap of Red Blood Cell Markers with Other Blood Cell Traits and/or Lipid
SNP Position A1/A2 AF (A2) Annotation Gene Trait Beta p Value
rs10903129 1: 25,768,937 A/G 0.568 intron TMEM57-RHD RDW 0.037 1.19 3 107
TC46 0.061 5.40 3 1010
PLT 0.021 7.06 3 106
rs3772219 3: 56,771,251 A/C 0.338 missense ARHGEF3 HCT* 0.028 2.38 3 109
HGB* 0.026 3.76 3 109
PLT 0.031 5.93 3 1010
rs442177 4: 88,030,261 G/T 0.595 intron AFF1 HGB 0.034 3.97 3 1013
TG40 0.031 1.00 3 1018
BASO 0.030 1.99 3 105
rs2954029 8: 126,490,972 A/T 0.439 intergenic TRIB1 RDW 0.036 1.53 3 107
TG40 0.076 1.00 3 107
rs55707100 15: 43,820,717 C/T 0.033 missense MAP1A HGB 0.071 1.65 3 108
PLT 0.095 7.03 3 1014
TG52 0.090 1.40 3 1017
rs4911241 20: 31,140,165 C/T 0.241 intron NOL4L MCV 0.040 1.25 3 108
RDW 0.043 5.79 3 108
BASO 0.051 1.35 3 1010
MONO 0.033 3.57 3 105
rs1800961 20: 43,042,364 C/T 0.032 missense HNF4A HCT 0.083 1.44 3 108
HGB 0.073 2.53 3 108
HDL40 0.127 2.00 3 1034
Shown here are significant novel variants from the RBC traits association analyses that overlap with other blood-cell traits or with lipids. Results for the white blood
cell and platelet traits are from the Blood Cell Consortium, and results for lipids are from the published literature. Results are presented for European-ancestry
individuals, except in the presence of an asterisk (*), which stands for result from ‘‘All’’ ancestry. The allele frequency and direction of the effect (beta) is given
for the A2 allele. Abbreviations are as follows: A1, reference allele; A2, alternate allele; AF, allele frequency; HCT, hematocrit; HGB, hemoglobin; MCV, mean
corpuscular volume; RDW, red blood cell distribution width; TC, total cholesterol; PLT, platelet; TG, triglycerides; WBC, white blood cells; BASO, basophils;
MONO, monocytes; HDL, HDL cholesterol.Acknowledgments
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